#DLBCL
LightNews LightNews
projectmedusattrpg.bsky.social
⭐️Beanie Babes⭐️

A TTRPG fundraising event to help @blizzb3ar.bsky.social take on DLBCL treatment 🧡
August 12, 2025 at 11:06 PM
harrisonk.bsky.social
The drugs.com AI is working spectacularly well
Searching drugs.com for penisomab. There is no result but the website offers to ask an AI agent. The drugs.com AI claims that penisonomab is a medication used to treat DLBCL. Asking the AI if penisomomab is a real. It responds that no, it is made up.
February 26, 2026 at 9:46 PM
doconco.bsky.social
Freue mich sehr mit den Patienten, die allen Wahrscheinlichkeiten trotzen.

Wie der mittlerweile 80-Jährige, der vor einigen Jahren einen aggressiven Lymphdrüsenkrebs hatte (DLBCL), der sofort nach intensiver Therapie (R-CHOP) zurückkehrte.
1/n
October 5, 2023 at 7:28 PM
grngma.bsky.social
I was part of a research study on a blood test to find cancer at an early stage, Pathfinder 2. Guess what my test was positive and I was diagnosed with stage 1 lymphoma (DLBCL). Treatment started early and now in remission for two years. Science is wonderful and truly lifesaving.
December 6, 2024 at 3:48 AM
vonkarstedtlab.bsky.social
Happy to share an incredibly efficient collaboration with @gianmaria-liccardi.bsky.social
: Ibrutinib cooperates with #ferroptosis induction to kill #dlbcl
www.nature.com/articles/s41...
Redox destabilization by ibrutinib promotes ferroptosis in diffuse large B-cell lymphoma (DLBCL) - Cell Death Discovery
Cell Death Discovery - Redox destabilization by ibrutinib promotes ferroptosis in diffuse large B-cell lymphoma (DLBCL)
www.nature.com
November 1, 2025 at 7:55 PM
thecandacemarie.bsky.social
LET’S GOOOOO!!!

Come raise money to help support @blizzb3ar.bsky.social through his DLBCL treatment as we play HONEY HEIST!!!

Twitch.tv/projectmedusa
A Black person in a green beanie and an olive tank with a gold chain wearing white headphones and black round glasses. They’re posing making a muscle in front of a black and purple background.
August 17, 2025 at 11:51 PM
remydulery.bsky.social
Here is a video where I discuss the management and treatment options for patients with DLBCL who are not eligible for CAR T-cell therapy.

#VuMedi #CAR_T #lymsm #Medsky

www.vumedi.com/video/treati...
Treating Patients With DLBCL Who Are Not Eligible for CAR-T Therapy
A video from Remy Dulery, posted on Dec 18, 2024.
www.vumedi.com
January 6, 2025 at 10:55 PM
katcollmd.bsky.social
#slidearchiveseries history of DLBCL s/p chemotherapy with residual retroperitoneal lymphadenopathy, s/p radiation therapy for bulky cauda equina leptomeningeal disease, now for management of prostate abscess #gupath #malakoplakia
March 29, 2025 at 2:35 PM
medihumdani.bsky.social
CD19.20 dual CAR in third or later line DLBCL being presented by @niravshahmd #ASH24
December 7, 2024 at 6:37 PM
ronthinkmedia.bsky.social
WTF?!? That biopsy BS is like deadly science fiction. I had diffuse large B-cell lymphoma (DLBCL) in 2021. Everything in the "basics of cancer" article is spot on. It's a great resource. Glad the doctor shared it. And I'm sending you the most robust digital "kick ass" possible for your treatment. 👊🏼🤜🏼
January 19, 2025 at 7:28 AM
drmikedickinson.bsky.social
Great to be at #ASH24 and to be in the 1L DLBCL session. Cudos to @adrian
December 8, 2024 at 9:56 PM
gianmaria-liccardi.bsky.social
Fantastic work in collaboration with @vonkarstedtlab.bsky.social available on Cell Death & Discovery. Ibrutinib sensitises to ferroptosis induction to kill DLBCL. #cancer #lymphoma #dlbcl

doi.org/10.1038/s414...
November 1, 2025 at 8:06 PM
mitchell.science
New paper led by Aimilia Vareli out now.
nature.com/articles/s41...
The lymphoma microenvironment stops BH3-mimetics working.
In vitro/vivo/silico, we find inhibition of NFκB makes BH3-mimetics great again.🧵
@sussexbcr.bsky.social @bsmsmedschool.bsky.social @leukaemiauk.bsky.social @sussexcancer.org
Systems biology-enabled targeting of NF-κΒ and BCL2 overcomes microenvironment-mediated BH3-mimetic resistance in DLBCL - Cell Death & Disease
Cell Death & Disease - Systems biology-enabled targeting of NF-κΒ and BCL2 overcomes microenvironment-mediated BH3-mimetic resistance in DLBCL
nature.com
August 18, 2025 at 11:05 AM
5ummerheat.bsky.social
did my online consult with doctor who's handling my case at the cancer center in another city. lots of good information.
i have non hodgkins diffuse large b cell lymphoma (DLBCL).
learning about the chemo and its effects was interesting. gonna be a bit of a long road yet.
April 29, 2026 at 10:45 PM
jkuball.bsky.social
Excellent presentation of ⁦‪@CChabannon‬⁩ on tisagenlecleucel for the Management of Patients with R/R DLBCL: an Interim Report of the European PASS Conducted
by EBMT ⁦at #ASH24
December 10, 2024 at 6:12 PM
jamesnolan.bsky.social
🧵1/Exciting news in cancer epigenetics! Our latest research, "AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma", is now available on www.biorxiv.org/content/10.1.... Here's a thread summarizing our findings!👇
#CancerResearch #Epigenetics #Chromatin #Lymphoma
AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma
The catalytic subunit of Polycomb Repressive Complex 2 (PRC2), EZH2, is recurrently mutated in 25% of diffuse large B-cell lymphomas (DLBCL), causing increased H3K27me3 and decreased H3K27me2 levels. ...
www.biorxiv.org
October 17, 2025 at 7:11 AM
oncodaily.bsky.social
Real-world Experience with CD20-directed BsAbs in R/R DLBCL - Yan Leyfman

@yleyfman.bsky.social

oncodaily.com/voices/cd20-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Yan Leyfman: Real-world Experience with CD20-directed BsAbs in R/R DLBCL - OncoDaily
Yan Leyfman: Real-world Experience with CD20-directed BsAbs in R/R DLBCL / Adrienne N Nedved, Ajay Major, Alex Niu, Alyssa Gibson, Boyu Hu, Brian T. Hill,
oncodaily.com
November 4, 2025 at 8:42 PM
myesmo.bsky.social
📣 New ESMO #ClinicalPracticeGuideline on #lymphomas: evidence-based recommendations for all major #lymphoma subtypes, updated as needed as an ESMO Living Guideline, reflecting developments in Tx.
#DLBCL #PCNSL #FollicularLymphoma #HodgkinLymphoma #ESMOGuidelines

🔗 buff.ly/2ZYJc2c
August 5, 2025 at 9:12 AM
biorxiv-cancer.bsky.social
Integrating Epstein-Barr virus (EBV) status into diffuse large B cell lymphoma (DLBCL) genetics https://www.biorxiv.org/content/10.64898/2026.04.03.710620v1
April 5, 2026 at 1:49 AM
gtresearch.bsky.social
Researchers from Georgia Tech, Emory, @mdanderson.bsky.social, and Weill Cornell are tackling health disparities in lymphoma treatment. Using immunoengineering, they aim to improve outcomes for African American and EBV-related DLBCL patients. b.gatech.edu/4iaPpOY
November 27, 2024 at 9:47 PM
vpizzuti.bsky.social
I am happy to announce I was selected by @ash.hematology.org to receive the ASH HONORS Award!

Excited for this project studying PET/CT radiomics in DLBCL. Grateful to Dr. Manali Kamdar for her mentorship & ASH!
#ASHAwards #Fight4Hematology
@cudeptofmedicine.bsky.social
@cuhematology.bsky.social
July 16, 2025 at 5:41 PM
ihi-synthia.bsky.social
💜 On #RareDiseaseDay2025, we reaffirm our commitment to driving data-driven innovation for rare diseases. In SYNTHIA, we focus on 6 use cases among which Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL) #RareDiseaseDay #MultipleMyeloma #MM #Lymphoma #DLBCL #hematology #datascience
February 26, 2025 at 11:41 PM
mskcancercenter.bsky.social
“These findings compare favorably with R-CHOP alone and support the ongoing phase 3 trial of epcoritamab + R-CHOP in 1L DLBCL.”

MSK lymphoma specialist Dr. Lorenzo Falchi shared new research today at @ash-hematology.bsky.social.

#ASH24

Learn more:
bit.ly/4goJHaK
December 8, 2024 at 11:43 PM
tumscvdri.bsky.social
#MicroRNAs, especially miR-21 and miR-155, show promise as diagnostic and prognostic #biomarkers in diffuse large B-cell lymphoma (DLBCL), with strong accuracy and survival prediction. #DLBCL #Oncology onlinelibrary.wiley.com/doi/10.1002/...
ROC curve for the diagnostic accuracy of miRNA in DLBCL.
July 19, 2025 at 7:24 AM
majorajay.bsky.social
From the UChicago Kline Lab in @bloodjournal.bsky.social: multi-omic characterization of 4 'immune quadrants' in DLBCL, with better response to bispecifics (but not CAR-T) in "GCB Hot" versus "GCB Cold." #lymsm #tcellrx https://ashpublications.org/blood/article/doi/10.1182/blood.2024025355/535294/I…
January 27, 2025 at 9:46 PM